Date | Title | Description | Source |
22.03.2024 | Antengene Announces Full Year 2023 Financial Results, Highli... | Promising clinical activities and efficacies during dose escalations for four lead global rights pro... | en.prnasia... |
20.03.2024 | Antengene Initiates Phase II Dose Expansion Study of Claudin... | SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
20.03.2024 | Antennova Completes First Dosing Cohort for Anti-CD24 mAb, A... | ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncolog... | en.prnasia... |
20.03.2024 | Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispeci... | SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
06.03.2024 | Antengene to Present Four Preclinical Abstracts at AACR 2024... | The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as wel... | en.prnasia... |
14.12.2023 | Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023... | SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
06.12.2023 | Antengene Announces XPOVIO® Regulatory Approval in Macau for... | XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau.
XPOVIO® has... | en.prnasia... |
17.11.2023 | Antengene Presents Encouraging Clinical Data from Four Pipel... | Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibo... | en.prnasia... |
08.11.2023 | Antengene to Host 2023 R&D Day and Discuss Key Data with... | During the event, Antengene will review promising data of its R&D pipeline, including ATG-031 (a... | en.prnasia... |
01.11.2023 | Antengene Presents Results from Five Investigational Program... | SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
28.09.2023 | Antengene To Present Results From Five Studies at 2023 SITC ... | SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
21.09.2023 | Antengene Announces Phase I Study of Anti-CD24 Monoclonal An... | - The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, imm... | en.prnasia... |
25.08.2023 | Antengene Announces Interim Financial Results for 2023 with ... | SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
11.08.2023 | Antengene Enters into Commercialization Partnership with Han... | - Antengene and Hansoh Pharma to enter into collaboration agreement involving commercialization of X... | en.prnasia... |
18.07.2023 | Antengene Announces First Patient Dosed in the Nivolumab Com... | - ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusive ... | en.prnasia... |
17.07.2023 | Antengene Announces XPOVIO® Regulatory Approval in Hong Kong... | XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong
XPOVIO® has received ... | en.prnasia... |
01.06.2023 | Antengene Announces XPOVIO® plus Bortezomib and Dexamethason... | - XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor a... | en.prnasia... |
26.05.2023 | Antengene To Present Latest Results from TORCH-2 Study of AT... | The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 monoclo... | en.prnasia... |
23.05.2023 | Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG... | SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
18.05.2023 | Antengene Announces Clearance of U.S. IND for the Phase I Tr... | ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to ... | en.prnasia... |
17.05.2023 | Antengene Announces NDA Submission for XPOVIO® in Indonesia | SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
27.04.2023 | Antengene to Release Latest Results from the TORCH-2 Trial o... | SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
17.04.2023 | Antengene Announces Five Presentations at the 2023 American ... | Five posters showcased progress with multiple preclinical and clinical programs, including ATG-008 (... | en.prnasia... |
29.03.2023 | Antengene Announces First Patient Dosed with Claudin 18.2 An... | Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate... | en.prnasia... |
28.03.2023 | Antengene Announces Results for Full Year 2022 with Updates ... | SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
20.03.2023 | Antengene Announces Five Upcoming Presentations at the 2023 ... | – Five posters will showcase progress with multiple preclinical and clinical programs, including the... | en.prnasia... |
14.03.2023 | Antengene Announces IND Approval for the Phase I CLINCH Tria... | - Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjuga... | en.prnasia... |
03.01.2023 | Antengene to Present at the 41st Annual J.P. Morgan Healthca... | SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
27.12.2022 | Antengene Enters into a Global Clinical Collaboration with M... | - ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti... | einpresswi... |
27.12.2022 | Antengene Enters into a Global Clinical Collaboration with M... | - ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti... | en.prnasia... |
23.12.2022 | Antengene Announces NDA Submission for XPOVIO® in Macau, Mal... | SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
09.12.2022 | Antengene Announces HREC Approval in Australia for the Phase... | Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting the... | en.prnasia... |
08.12.2022 | Antengene Appoints Amily Zhang as its Chief Medical Officer | SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
07.12.2022 | Antengene Appoints Amily Zhang as its Chief Medical Officer | SHANGHAI and HONG KONG, Dec. 6, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | einpresswi... |
15.11.2022 | Antengene Highlights Encouraging ATG-008 Efficacy Results Fr... | An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in ... | en.prnasia... |
11.11.2022 | Antengene Presents Promising Results from Four Preclinical S... | - Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoc... | einpresswi... |
11.11.2022 | Antengene Presents Promising Results from Four Preclinical S... | - Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 monoc... | en.prnasia... |
07.11.2022 | Preliminary Results from Two Clinical Studies of Selinexor t... | - Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeuti... | en.prnasia... |
02.11.2022 | Antengene Announces IND Approval for the Phase I STAMINA-001... | - ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to ente... | en.prnasia... |
31.10.2022 | Antengene Receives U.S. FDA Clearance of IND Application for... | ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to d... | en.prnasia... |
27.10.2022 | Antengene to Host Research and Development Day on November 1... | Virtual English Session:
Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time
November 15 at 9:30... | en.prnasia... |
21.10.2022 | Antengene Announces XPOVIO® Regulatory Approval in Taiwan fo... | - XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan
- Antengene plans to ... | en.prnasia... |
08.10.2022 | Antengene Announces Upcoming Presentations at the 2022 Socie... | Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclona... | einpresswi... |
08.10.2022 | Antengene Announces Upcoming Presentations at the 2022 Socie... | Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclona... | en.prnasia... |
19.09.2022 | Antengene Announces ATG-101 Granted Orphan Drug Designation ... | SHANGHAI and BUCKS COUNTY, Pa., Sept. 20, 2022 /PRNewswire/ -- Antengene Corporation Limited ("... | en.prnasia... |
14.09.2022 | Antengene Unveils Its First Australian Office to Continue Ex... | SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveiled a new office spac... | en.prnasia... |
09.09.2022 | Antengene to Present at Upcoming Industry Conferences | SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
01.09.2022 | Antengene Announces XPOVIO® Included for Reimbursement by th... | XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor app... | en.prnasia... |
31.08.2022 | Antengene Announces Interim 2022 Financial Results and Provi... | - Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Main... | en.prnasia... |
16.08.2022 | Antengene Announces First Patient Dosed of Small Molecule AT... | ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavail... | en.prnasia... |
03.08.2022 | Antengene Announces First Patient Dosed in the PROBE-CN Stud... | ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed molec... | en.prnasia... |
19.07.2022 | Antengene Announces Research Collaboration with Celularity t... | - This research collaboration marks Antengene's entry into the field of cellular medicines.
SHANGHAI... | en.prnasia... |
27.06.2022 | Antengene Announces Clinical Trial Collaboration with BeiGen... | - Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint inhibi... | en.prnasia... |
08.06.2022 | Antengene Announces First Patient Dosed in the Phase I STAMI... | SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
07.06.2022 | Antengene Announces HREC Approval in Australia for the Phase... | – Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, ... | en.prnasia... |
01.06.2022 | Antengene to Present Clinical Results of ATG-008 (Onataserti... | Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and t... | en.prnasia... |
23.05.2022 | Antengene Announces First Patient Dosed in the Phase I/II SW... | SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
18.05.2022 | Antengene Announces XPOVIO® Treatment Regimens Included for ... | SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
16.05.2022 | Antengene Announces Commercial Availability of XPOVIO® (Seli... | -Distribution channels in place to streamline/facilitate patient access.
-XPOVIO® will be available ... | en.prnasia... |
13.05.2022 | Antengene Announces Addition of Multiple XPOVIO® Treatment R... | SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
13.05.2022 | Antengene Announces XPOVIO® (selinexor) Data to be Presented... | SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
06.05.2022 | Antengene to Participate in Three Upcoming Investor Conferen... | CICC Healthcare Industry Forum 2022: May 9th to 12th
BTIG Virtual China Biotech Day: June 1st
Citi's... | en.prnasia... |
29.04.2022 | Antengene Announces Latest Clinical Trial Data of ATG-008 (o... | SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
27.04.2022 | Antengene Announces Submission to the Human Research Ethics ... | Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small mole... | en.prnasia... |
11.04.2022 | Antengene Announces Publication of Five Posters at the 2022 ... | The company will present the preclinical data of five novel drug candidates at AACR 2022 (on April 8... | en.prnasia... |
06.04.2022 | Antengene's Pivotal "MARCH" Study to Evaluate Seli... | - Results showed an overall response rate (ORR) of 29.3% for all treated patients.
- Consistent resp... | en.prnasia... |
30.03.2022 | Antengene Announces IND Approval in China for a Phase II Stu... | This study is the third ATG-016 study to be conducted in China.
Study highlights Antengene's robust ... | en.prnasia... |
18.03.2022 | Antengene Announces 2021 Full Year Financial Results and Pro... | SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengen... | en.prnasia... |
10.03.2022 | Antengene Announces IND Approval in China for the Phase I St... | - The novel bispecific antibody ATG-101 is Antengene's first in house developed molecule with global... | en.prnasia... |
09.03.2022 | Antengene Announces XPOVIO® Approved by the TGA in Australia... | - XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed and/... | en.prnasia... |
09.03.2022 | Antengene Announces Five Upcoming Presentations at the 2022 ... | Posters Showcase Early-Stage Clinical and Preclinical Pipeline.
Focus on ATG-037, ATG-018, ATG-022, ... | en.prnasia... |
02.03.2022 | Antengene Announces XPOVIO® Regulatory Approval in Singapore... | SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
07.02.2022 | Antengene Announces HREC Approval in Australia for the Phase... | SHANGHAI and HONG KONG, Feb. 7, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
05.01.2022 | Antengene to Present at the 40th Annual J.P. Morgan Healthca... | SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
20.12.2021 | First Patient Dosed in Australia in ATG-101 First-in-Human T... | SHANGHAI AND HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
17.12.2021 | Antengene Announces NDA Approval by NMPA for XPOVIO®, China'... | SHANGHAI and HONG KONG, Dec. 17, 2021 /PRNewswire/ -- Antengene Corporation Limited (the "Compa... | en.prnasia... |
16.12.2021 | Antengene and XtalPi Announce AI-Driven R&D Collaboratio... | SHANGHAI and HONG KONG, Dec. 16, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
14.12.2021 | Antengene Presents Results of Phase 1b TOUCH Trial of Seline... | SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
13.12.2021 | Antengene Announces Clinical Collaboration with Bristol Myer... | ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor
Combinatio... | en.prnasia... |
13.12.2021 | Antengene Announces Clinical Collaboration with Bristol Myer... | ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor
Combinatio... | marketscre... |
26.11.2021 | Antengene Included in the MSCI Global Small Cap Indexes - MS... | SHANGHAI and HONG KONG, Nov. 26, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene... | en.prnasia... |
25.10.2021 | Antengene to Host its First R&D Days on November 16 and ... | Virtual Event (in English) on November 16
On Site Event with Live Webcast (in Mandarin) on Nov 18
SH... | en.prnasia... |
23.08.2021 | Antengene Announces Approval of the Phase II Study of Seline... | | prnewswire... |
01.08.2021 | Antengene Announces the Approval of First-in-Class Oral XPO1... | | prnewswire... |
21.07.2021 | Antengene Announces The Approval by Human Research Ethics Co... | | prnewswire... |
05.07.2021 | Antengene Announces Acceptance of IND Application in China f... | | prnewswire... |
18.06.2021 | Antengene Provides an Update on Its Latest Developments | | prnewswire... |
08.06.2021 | Antengene's Partner Karyopharm Therapeutics Announces Update... | | prnewswire... |
03.06.2021 | Antengene Announces Publication of Abstract on XPO1 Inhibito... | | prnewswire... |
01.06.2021 | Antengene Announces Abstracts on Twelve Clinical Studies of ... | | prnewswire... |
01.06.2021 | Antengene Announces Fifteen Clinical Studies and Results of ... | | prnewswire... |
27.05.2021 | Antengene Announces First Patient Dosed in Phase I/II Trial ... | | prnewswire... |
25.05.2021 | Antengene Appoints Kathryn Gregory as Vice President and Hea... | SHANGHAI and HARTFORD, Conn., May 25, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Ante... | en.prnasia... |
17.05.2021 | Antengene Announces the Completion of the Quantitative and S... | SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene&... | en.prnasia... |
17.05.2021 | Antengene and Calithera Biosciences Enter into Worldwide Exc... | SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited... | en.prnasia... |
13.05.2021 | Antengene Announces the Completion of Its Manufacturing Cent... | | prnewswire... |
13.05.2021 | Antengene Announces the IND Approval for Eltanexor in Patien... | | prnewswire... |
12.05.2021 | Antengene Announces IND Approval in China for a Global Phase... | | prnewswire... |
23.11.2020 | Qiming’s Portfolio Company Antengene Lists on Main Board of ... | Clinical-stage Asia-Pacific biopharmaceutical company Antengene (SEHK: 6996) officially listed on th... | finsmes.co... |
20.07.2020 | Fidelity leads $97m Series C round in Chinese biopharma Ante... | Premium
Antengene Corporation, a Chinese biopharma firm that develops therapies in the haematology a... | dealstreet... |